Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience

BACKGROUND: In 2011, we reported the outcomes of pancreatic cancer (PC) patients enrolled in phase I trials at our institution from 2004 through 2009. At the time, gemcitabine and erlotinib were the only Food and Drug Administration-approved drugs for PC and median overall survival (OS) from consult...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldstein, Jennifer B., Tang, Chad, Hess, Kenneth R., Hong, David, Subbiah, Vivek, Janku, Filip, Fu, Siqing, Karp, Daniel D., Naing, Aung, Tsimberidou, Apostolia Maria, Wheler, Jennifer, Zinner, Ralph, Javle, Milind, Varadhachary, Gauri R., Wolff, Robert A., Fogelman, David R., Meric-Bernstam, Funda, Piha-Paul, Sarina A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675623/
https://www.ncbi.nlm.nih.gov/pubmed/29152071
http://dx.doi.org/10.18632/oncotarget.19897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675623/
https://www.ncbi.nlm.nih.gov/pubmed/29152071
http://dx.doi.org/10.18632/oncotarget.19897

Ejemplares similares